Roche

What Roche does

Roche is a global pharmaceutical and diagnostics company, with its German operations representing the second-largest country footprint within the global Roche Group. The company operates two core segments — Pharmaceuticals and Diagnostics — spanning the full value chain in Germany from R&D through manufacturing, logistics, marketing, and sales. Approximately 18,000 employees work across five major German sites: Grenzach-Wyhlen (pharma headquarters and manufacturing), Mannheim (diagnostics headquarters, European distribution hub, and diabetes care), Penzberg (major biotech R&D center with ~7,900 employees), Ludwigsburg (diagnostics automation solutions), and Potsdam (signature diagnostics).

The pharmaceutical portfolio includes monoclonal and bispecific antibodies such as Herceptin (trastuzumab), Avastin (bevacizumab), Tecentriq (atezolizumab, available in both IV and subcutaneous forms), Ocrevus (ocrelizumab), Hemlibra (emicizumab), Vabysmo (faricimab), Gazyvaro (obinutuzumab), Columvi (glofitamab), Lunsumio (mosunetuzumab), and Alecensa (alectinib), alongside targeted small molecules (Cotellic, Zelboraf), antibody-drug conjugates (Polivy), and splicing modifiers (Evrysdi). The diagnostics business delivers in vitro diagnostics, point-of-care, molecular, tissue, and sequencing solutions to clinical laboratories and hospitals worldwide, generating recurring revenue from reagents and consumables tied to installed instrument platforms; the diabetes care unit sells Accu-Chek blood-glucose monitoring systems.

Roche generates revenue primarily through prescription pharmaceuticals sold to hospitals, specialty physicians, and pharmacies, reimbursed via public and private health systems, complemented by recurring instrument/reagent revenue in diagnostics and hardware sales in diabetes care. Go-to-market leverages a direct field sales force targeting HCPs and hospital procurement, a dedicated Fachportal professional portal, medical congress participation (ASCO, ESMO, ECTRIMS, etc.), patient access programs, pharmacy/wholesale distribution (including MSV3 electronic ordering and Central Government Health Scheme enrollment in India), and a centralized European Diagnostics Distribution Center in Mannheim serving more than 15 countries. The company's R&D integrates data and algorithms with laboratory research to advance personalized medicine, and supports companion diagnostics linking its therapeutic and diagnostic franchises.

Name

Roche

Legal name

F. Hoffmann-La Roche AG

Website

https://roche.de

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche is a global pharmaceutical and diagnostics company that develops and commercializes oncology, immunology, neuroscience, ophthalmology, and infectious-disease biologics (including Tecentriq, Herceptin, Ocrevus, Hemlibra, Vabysmo) alongside in vitro diagnostics, point-of-care testing, and Accu-Chek diabetes-care solutions for healthcare professionals, hospitals, laboratories, and patients.

Ownership category

akta.pro rank

Product category

Pharmaceuticals & Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Prescription pharmaceuticals
• In vitro diagnostics
• Biologic therapies
• Cancer treatments
• Blood glucose monitoring

Headquarters

HQ city

Mannheim

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Products: Roche generates the majority of its revenue through the sale of prescription pharmaceutical products across oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Products include Alecensa, Avastin, Tecentriq, Ocrevus, Hemlibra, Gazyvaro, Vabysmo, MabThera/Rituximab, Herceptin, Kadcyla, Perjeta, Phesgo, Columvi, Lunsumio, and others. Revenue is generated through direct hospital and pharmacy sales, with reimbursement through public and private health insurance systems globally.
2. In Vitro Diagnostics & Diagnostics Solutions: Roche's Diagnostics division provides laboratory diagnostics, point-of-care testing, molecular diagnostics, tissue diagnostics, and sequencing solutions. The division serves clinical laboratories, hospitals, and reference laboratories worldwide. Roche Diagnostics supplies research products and consumables alongside instrument platforms, generating recurring revenue from reagents and consumables.
3. Diabetes Care: Roche Diabetes Care offers blood glucose monitoring systems and diabetes management solutions under the Accu-Chek brand, serving patients and healthcare providers with devices, test strips, and digital health tools.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Roche researches, develops, manufactures, and markets proprietary prescription pharmaceuticals — including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and targeted small molecules — across oncology, immunology, neuroscience, ophthalmology, and hematology. The company separately operates an in vitro diagnostics division delivering clinical chemistry, immunoassay, molecular, tissue, and sequencing platforms to laboratories and hospitals, alongside Accu-Chek blood glucose monitoring systems for diabetes care under the Roche Diabetes Care business.

Product overview

Roche is a global pharmaceutical and diagnostics company offering a broad portfolio of branded pharmaceutical products across oncology, immunology, neuroscience, ophthalmology, and infectious diseases. The product portfolio includes monoclonal antibodies (Herceptin, Avastin, Actemra), bispecific antibodies (Hemlibra, Columvi, Lunsumio), immunotherapy drugs (Tecentriq, which is available in both IV and subcutaneous formulations), small molecule inhibitors (Alecensa, Cotellic, Zelboraf), and biological therapies (Evrysdi, Ocrevus, Enspryng). In ophthalmology, Vabysmo addresses retinal diseases, supported by the augenblicke patient support program and Retinora app. Diagnostics division provides testing solutions and laboratory equipment. The company operates through specialized therapeutic area portals and support services for healthcare professionals and patients.

Differentiator

Problem solved

Functional benefit

Brands

• Alecensa (Alectinib): Pharmaceutical product for ALK-positive NSCLC
• Avastin (Bevacizumab)
• Columvi (Glofitamab)
• Gazyvaro (Obinutuzumab)
• Hemlibra (Emicizumab)
• Herceptin (Trastuzumab)
• Ocrevus (Ocrelizumab)
• Tecentriq (Atezolizumab)
• Vabysmo (Faricimab)
• augenblicke
• Retinora

Products and services

• Tecentriq (Atezolizumab) PD-L1 inhibitor immunotherapy (available in both IV and subcutaneous forms) for lung cancer, breast cancer, urothelial carcinoma, and other malignancies; the SC formulation is the world's first subcutaneous PD-(L)1 inhibitor.
• Avastin (Bevacizumab) Anti-angiogenic monoclonal antibody for treatment of colorectal, lung, breast, kidney, and ovarian cancers.
• Herceptin (Trastuzumab) Monoclonal antibody for treatment of HER2-positive breast cancer and gastric cancer.
• Ocrevus (Ocrelizumab) Humanized monoclonal antibody targeting CD20 for relapsing multiple sclerosis and the only approved therapy for primary progressive MS.
• Hemlibra (Emicizumab) Bispecific monoclonal antibody for prophylactic treatment of hemophilia A, significantly reducing bleeding episodes.
• Gazyvaro (Obinutuzumab) Monoclonal antibody for B-cell malignancies (chronic lymphocytic leukemia, follicular lymphoma) and for active lupus nephritis (new EU indication).
• Vabysmo (Faricimab) Bispecific antibody simultaneously inhibiting Ang-2 and VEGF-A for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
• Columvi (Glofitamab) Bispecific CD20xCD3 antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), offering a fixed-duration treatment option.
• Polivy (Polatuzumab Vedotin) Antibody-drug conjugate for treatment of relapsed/refractory diffuse large B-cell lymphoma.
• Lunsumio (Mosunetuzumab) Bispecific antibody for treatment of relapsed or refractory follicular lymphoma.
• Alecensa (Alectinib) ALK inhibitor for treatment of ALK-positive non-small cell lung cancer.
• Evrysdi (Risdiplam) SMN2 splicing modifier for treatment of spinal muscular atrophy (SMA).
• Enspryng (Satralizumab) Monoclonal antibody for treatment of neuromyelitis optica spectrum disorder (NMOSD).
• Piasky (Crovalimab) Monoclonal antibody for treatment of paroxysmal nocturnal hemoglobinuria (PNH).
• Giredestrant Oral breast cancer drug (selective estrogen receptor degrader) for early-stage ER-positive breast cancer, showing 30% reduction in invasive disease recurrence or death in Phase 3 trials.
• Floodlight Digital Health Platform Smartphone-based multiple sclerosis monitoring application providing digital assessments and self-management tools for MS patients.
• Retinora App Digital companion app for patients with macular diseases (nAMD, DME, RVO), supporting therapy adherence and self-management during IVOM treatments.
• augenblicke Patient Support Programme Comprehensive patient support initiative providing education, telephone support, the Retinora companion app, and therapy adherence resources for patients with retinal diseases (nAMD, DME, RVO) treated with Vabysmo.
• Accu-Chek (Blood Glucose Monitoring) Blood glucose monitoring systems, test strips, and digital diabetes management tools sold under the Accu-Chek brand by Roche Diabetes Care to patients and healthcare providers.
• Roche In Vitro Diagnostics Platform Clinical chemistry, immunoassay, molecular, tissue, sequencing, and point-of-care diagnostics instrument platforms with recurring reagent and consumable revenue, sold to clinical laboratories, hospitals, and reference laboratories worldwide.

Quantifiable outcome

• Roche's subcutaneous Tecentriq reduces administration time by approximately 80 minutes per patient, potentially treating up to 5 patients in the time taken for 1 IV infusion.
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• NIPER Raebareli (National Institute of Pharmaceutical Education and Research, Raebareli)coreStrategic or Co-development Partner · 20 March 2026Roche Pharma India signed an MoU with NIPER Raebareli to establish academic-industry collaboration through certificate programs, guest lectures on AI in pharma research, scholarship opportunities via Roche's LEAP program, and faculty immersion initiatives. The partnership aims to bridge the gap between academic learning and industry practice while supporting India's goal of developing capabilities in regulatory sciences, biologics, and AI in pharmaceuticals.
• NIPER Mohali (National Institute of Pharmaceutical Education and Research, Mohali)coreStrategic or Co-development Partner · 1 February 2026Roche previously signed a similar MoU with NIPER Mohali in February 2026, extending its academic partnerships across multiple NIPER institutions in India. The partnership includes certificate programs, AI-focused guest lectures, LEAP scholarship program, and faculty immersion initiatives.
• Allianz der Chancen (Alliance of Opportunities)coreStrategic or Co-development PartnerRoche co-founded the Allianz der Chancen with more than 20 companies and institutions from different industries (including Bayer AG, Commerzbank, Deutsche Bahn, Deutsche Telekom, Siemens, thyssenkrupp, Infineon, and others), representing over one million employees. The alliance aims to address the transformation of the labor market, build bridges for employees through qualification programs, and combat skilled worker shortages. Roche contributed its experience with cross-industry career transition programs (e.g., retraining brewers as biotech technicians at Penzberg).
• The Valuable 500minorGTM or Marketing PartnerRoche has publicly committed to The Valuable 500, an organization dedicated to using the power of business to drive sustainable change for the 1.3 billion people worldwide with disabilities. Roche's commitment involves improving digital accessibility of its websites and corporate resources.

Scale indicators9 records

Recent moves11 records

Expansion highlights7 records

Market position

Strengths4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Roche_de
• YouTubeyoutube.com/playlist?list=PLmXzuVn0p6GA3mAUYu0F52bC6h6mM6LT5
• LinkedInlinkedin.com/company/roche-deutschland
• Instagraminstagram.com/roche_germany
• Facebookfacebook.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche